An international team developed and validated the first global classification criteria for pediatric chronic nonbacterial osteomyelitis, offering a standardized tool to improve research and diagnosis.
In the SURMOUNT-5 trial, tirzepatide led to a 20.2% mean weight loss in adults with obesity—significantly more than the 13.7% achieved with semaglutide.